

#### NIH HEAL INITIATIVE

## Structural Racism as a Key Determinant of Substance Use Outcomes

Wednesday, September 9, 2020

Hillary Kunins, MD, MPH, MS



NIH HEAL Initiative and Helping to End Addiction Long-term are service marks of the U.S. Department of Health and Human Services.

### Key Take Aways: Structural racism leads to adverse drug control policies and treatment practices, and worse substance use outcomes

- 1. Structural racism is a key determinant of adverse health and social outcomes among people who use drugs.
- 2. Among the effects of structural racism are drug control policies that worsen outcomes from substance use
- 3. Need an explicit antiracist approach to research, program, and policy to speed scientific and equitable solutions to the national opioid (and other drugs) public health crisis



#### Structural racism defined

- The totality of ways in which societies foster racial discrimination, through mutually reinforcing inequitable systems:
  - Housing, education, employment, earnings, benefits, credit, health care, criminal justice
- These systems reinforce discriminatory practices and distribution of resources, which together affect health outcomes.



### Shifting overdose demographics

- As the face of the heroin epidemic perceived to be a white problem, new mantra:
  - "We can't arrest our way out of the problem."
- In New York City, overdose deaths among Black New Yorkers increased in 2017, exceeding rates among white New Yorkers
- Without addressing the structural racism that undergirds the overdose epidemic in Black, indigenous and communities of color, punitive approaches again become normative (not that they have stopped)

### Example 1: Criminalization of Black people during "War on Drugs" to present

- Key drug laws heightened punishment
  - New York State Rockefeller Drug Laws of 1973 spread nationally (mandatory sentencing)
  - Anti-Drug Abuse Act of 1986 (more severe criminal penalties for solid vs powder cocaine)
- Discriminatory enforcement of drug laws by race





# Similar proportions of drug use among Blacks and whites; disproportionate drug-related arrests and incarceration

Rates of Drug Use and Sales, by Race

Rates of Drug-Related Criminal Justice Measures, by Race

At the state level, blacks are about 6.5 times as likely as whites to be incarcerated for drug-related crimes.





Source: BLS n.d.c: Carson 2015: Census Bureau n.d.: EBI 2015: authors' calculations





## Consequences of drug use mediated through inequitably-applied criminal justice and social service policies

- Criminal justice and social service policies cause health and social harms
  - E.G.: Criminal justice history may preclude access to housing; housing associated with better substance use outcomes
- Discriminatory enforcement of drug laws by race causes the drug use consequences to vary by race



## Consequences of drug use mediated through inequitably-applied criminal justice and social service policies

"Imagine you are Erma Faye Stewart, a 30-year old African American single mother of two. You are arrested as part of a drug sweep in Texas. You spend a week in jail, you have no one to care for your children and are eager to get home. Your court-appointed lawyer urges you to plead guilty to distribution, saying the prosecutor has offered probation. You refuse, steadfastly proclaiming innocence.

After a month in jail, you decide to plead guilty so you can return home to your children. Unwilling to risk trial and years of imprisonment, you are sentenced to 10-years probation, \$1,000 fine, as well as court costs. You are now branded a drug felon. You are no longer eligible for food stamps, you may be discriminated against in employment; you cannot vote for 12-years; and you are about to be evicted from public housing. Once homeless, your children will be taken from you and put in foster care."



## Example 2: Inequitable access to effective treatment for opioid use disorder

- Buprenorphine was the second FDA-approved drug for opioid use disorder since methadone
- Inequitable availability of buprenorphine treatment for white and wealthy people resulted from racially targeted marketing strategies and inadequate insurance reimbursement
- Flexibility and privacy afforded by buprenorphine (compared to methadone) less available to people of color
- Opportunity for social integration and employment diminished by restrictive access to more flexible treatment (needs study)



### Example 3: Judicious opioid prescribing applied inequitably

- Opioid analgesic prescribing is an appropriate focus to decrease overdose deaths
- Reconsideration of prescribing practices underway
- Prior studies:
  - Black and other patients of color less likely to be prescribed effective pain medications
- Emerging evidence:
  - Black patients receive disparate opioid monitoring, tapering and discontinuation
    - Opioid discontinuation for Black patients 2.1 and 3.3 times more likely than white patients because of cannabis or cocaine use respectively
    - Opioid dose reduction among Black patients more likely during pain treatment compared to white patients
- Need to undo racist application of prescribing policy and continuously assess impact of policy change by race



### **Conclusions**

- Consequences of structural racism against people of color have perpetuated punitive approaches and diminished the effectiveness of public health-oriented approaches to drugs
- We will reproduce structural racism without deliberate anti-racist practice
- Need an explicit anti-racist public health approach to advance science and create equitable outcomes in the national overdose crisis



### Thank you

## Tools for antiracist public health practice

- Develop and assess programs that are placebased, multisector, and explicitly address racial equity
- Prioritize policy reform: change policies that adversely and disproportionately affect Black and other people of color
- Study and correct differential impact of policy and practice on Black and other people of color

